ибупрофен

Incompatibilities

Capsules; Coated tablet; Film-coated tablet; Gel for external use; Ointment for external use; Rectal suppositories for children; Substance; Substance-powder; Substance-powder for the preparation of non-sterile dosage forms; Sugar coated tablets; Suspension for ingestion for childrenCapsule, soft; Suppository; Tablets, effervescentSyrup; Tablets of prolonged action, coatedSolution for intravenous administration

None known.

Not applicable

None.

Ибупрофен solution must not be in contact with any acidic solution such as certain antibiotics or diuretics. A rinse of the infusion line must be performed between each product administration.

Preclinical safety data

Capsules; Coated tablet; Film-coated tablet; Gel for external use; Ointment for external use; Rectal suppositories for children; Substance; Substance-powder; Substance-powder for the preparation of non-sterile dosage forms; Sugar coated tablets; Suspension for ingestion for childrenCapsule, soft; Suppository; Tablets, effervescentSyrup; Tablets of prolonged action, coatedSolution for intravenous administration

No relevant information additional to that already contained elsewhere in the SmPC.

No relevant information, additional to that contained elsewhere in the SPC.

None stated.

There are no preclinical data considered relevant to clinical safety beyond data included in other sections of this Summary of Product Characteristics. With the exception of an acute toxicity study, no further studies have been carried out in juvenile animals with Ибупрофен.

Ибупрофен price

We have no data on the cost of the drug.
However, we will provide data for each active ingredient

Pharmacotherapeutic group

Capsules; Coated tablet; Film-coated tablet; Gel for external use; Ointment for external use; Rectal suppositories for children; Substance; Substance-powder; Substance-powder for the preparation of non-sterile dosage forms; Sugar coated tablets; Suspension for ingestion for childrenSolution for intravenous administration Propionic acid derivatives.other cardiac preparations, ATC code: C01 EB16

Special precautions for disposal and other handling

Capsules; Coated tablet; Film-coated tablet; Gel for external use; Ointment for external use; Rectal suppositories for children; Substance; Substance-powder; Substance-powder for the preparation of non-sterile dosage forms; Sugar coated tablets; Suspension for ingestion for childrenCapsule, soft; Suppository; Tablets, effervescentSyrup; Tablets of prolonged action, coatedSolution for intravenous administration

Not applicable.

Not applicable

None.

Administrative data

As for all parenteral products, ampoules of Ибупрофен should be visually inspected for particulate matter and the integrity of the container prior to use. Ampoules are intended for single use only, any unused portions must be discarded.

Chlorhexidine must not be used to disinfect the neck of the ampoule as it is not compatible with the Ибупрофен solution. Therefore, for asepsis of the ampoule before use, ethanol 60% or isopropyl alcohol 70% is recommended.

When disinfecting the neck of the ampoule with an antiseptic, to avoid any interaction with the Ибупрофен solution, the ampoule must be completely dry before it is opened.

The required volume to be given to the infant should be determined according to body weight, and should be injected intravenously as a short infusion over 15 minutes, preferably undiluted.

Use only sodium chloride 9 mg/ml (0.9%) solution for injection or glucose 50 mg/ml (5%) solution to adjust injection volume.

The total volume of solution injected to preterm infants should take into account the total daily fluid volume administered. A maximal volume of 80 ml/kg/day on the first day of life should usually be respected; this should be progressively increased in the following 1-2 weeks (about 20 ml/kg birthweight/day) up to a maximal volume of 180 ml/kg birthweight/day.

Before and after administration of Ибупрофен, to avoid contact with any acidic solution, rinse the infusion line over 15 minutes with 1.5 to 2 ml of either sodium chloride 9 mg/ml (0.9%) or glucose 50 mg/ml (5%), solution for injection.

After first opening of an ampoule, any unused portions must be discarded.

Any unused product or waste material should be disposed of in accordance with local requirements.